AHA Hypertension Scientific Sessions 2025

Richmond Pharmacology are pleased to announce our participation in the American Heart Association’s Hypertension Scientific Sessions 2025, held in Baltimore from 4–7 September.

Representing Richmond at Hypertension 2025:

• Dr Jörg Täubel, Chief Executive Officer
• James Rickard, Chief Scientific Officer

Our team will be available to discuss Richmond’s expertise in:

• Early-phase hypertension and cardiovascular research
• First-in-human and dose-response studies
• Ambulatory BP monitoring and novel endpoints
• Regulatory strategy and global trial delivery
• Targeted recruitment and patient-centric design

 If you’re attending Hypertension 2025 and seeking a partner in hypertension clinical development, we welcome meeting requests at: info@richmondpharmacology.com

Learn more: Hypertension Programming - Professional Heart Daily | American Heart Association

‍